FAQ on Telomir Pharmaceuticals' $3M Equity Investment and Age-Reversal Pipeline

What is Telomir Pharmaceuticals’ recent financial achievement?

Telomir Pharmaceuticals announced a $3 million equity investment from The Bayshore Trust, its largest shareholder, through the purchase of 1 million restricted shares at $3.00 each, an 18% premium to the stock’s prior closing price.

How will the $3 million investment be used?

The investment will support the advancement of Telomir Pharmaceuticals’ pipeline, including Telomir-1, a first-in-class age-reversal molecule, and Telomir-Ag2, a stabilized Silver(II) compound targeting drug-resistant infections.

What is Telomir-1?

Telomir-1 is a novel small molecule designed to lengthen the DNA’s protective telomere caps, which are crucial in the aging process, with the aim of promoting longevity and enhancing overall quality of life.

What are the next steps for Telomir-1?

An Investigational New Drug (IND) submission for Telomir-1 is planned by year-end, with a focus on rare disease indications to demonstrate early efficacy.

Who is the largest shareholder of Telomir Pharmaceuticals?

The Bayshore Trust is the largest shareholder of Telomir Pharmaceuticals, as evidenced by the recent $3 million equity investment.

What is the significance of the premium price paid for the shares?

The premium price of $3.00 per share, which is 18% above the stock’s prior closing price, reflects strong confidence from The Bayshore Trust in Telomir Pharmaceuticals’ potential and pipeline.

Where can I find more information about Telomir Pharmaceuticals?

For more information about Telomir Pharmaceuticals, visit their website at www.Telodx.com or the company’s newsroom at https://ibn.fm/TELO.

What is the total equity investment Telomir Pharmaceuticals has received from affiliated entities?

The recent $3 million investment brings the total equity investment from affiliated entities to $4 million, complemented by an undrawn $5 million non-dilutive credit line.

What is Telomir Pharmaceuticals’ approach to financing?

CEO Erez Aminov emphasized the company’s commitment to shareholder-friendly financing with no warrants or toxic structures, ensuring a sustainable approach to funding its research and development efforts.